Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 1, 2011, Pages 193-205

  Ferdinandi, Eckhardt S ^a   Vassilakos, Aikaterini ^a   Lee, Yoon ^a   Lightfoot, Jeff ^a   Fitsialos, Dimitri ^a   Wright, Jim A ^a   Young, Aiping H ^a  

^a Lorus Therapeutics Inc   (Canada)

Author keywords

Antisense; Oligonucleotide; Ribonucleotide reductase; Toxicity

Indexed keywords

DRUG METABOLITE; GTI 2040; MESSENGER RNA; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN SUBUNIT; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE R2; UNCLASSIFIED DRUG;

ADRENAL DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN TOXICITY; CARDIOTOXICITY; COMPLEMENT ACTIVATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG KIDNEY LEVEL; DRUG LIVER LEVEL; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SPLEEN LEVEL; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EMBRYO; FEMALE; LIVER TOXICITY; LUNG TOXICITY; LYMPHADENOPATHY; MALE; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NONHUMAN; ORGAN WEIGHT; PALLOR; PARTIAL THROMBOPLASTIN TIME; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RHESUS MONKEY; SINGLE DRUG DOSE; SPLEEN DISEASE; SPRAGUE DAWLEY RAT; THYMUS DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; TOXICOKINETICS; UTERUS DISEASE; WEAKNESS; WEIGHT CHANGE;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MACACA MULATTA; MALE; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; RATS; RATS, SPRAGUE-DAWLEY; RIBONUCLEOTIDE REDUCTASES; RNA, MESSENGER;

EID: 79959624824     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1473-z     Document Type: Article

References (34)

1. Hurta RA, Wright JA (1992) Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent. J Biol Chem 267:7066-7071
2. Reichard P (1993) From RNA to DNA, why so many ribonucleotide reductases? Science 260:1773-1777
3. Lewis WH, Kuzik BA, Wright JA (1978) Assay of ribonucleotide reduction in nucleotide-permeable hamster cells. J Cell Physiol 94:287-298 (Pubitemid 9095702)
4. Fan H, Villegas C, Wright JA (1996) Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA 93:14036-14040 (Pubitemid 26424241)
5. Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A (2003) GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 63:2802-2811 (Pubitemid 36667151)
6. Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA (1997) Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 12:383-393
7. Agrawal S, Zhao Q, Jiang Z, Oliver C, Giles H, Heath J, Serota D (1997) Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev 7:575-584 (Pubitemid 28039219)
8. Henry SP, Monteith D, Levin AA (1997) Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 12:395-408
9. Henry SP, Templin MV, Gillett N, Rojko J, Levin AA (1999) Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol 27:95-100 (Pubitemid 29075751)
10. Monteith DK, Levin AA (1999) Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol Pathol 27:8-13 (Pubitemid 29075737)
11. Shao J, Zhou B, Chu B, Yen Y (2006) Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6:409-431 (Pubitemid 44033390)
12. Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ (2005) A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 16:958-965 (Pubitemid 40903923)
13. Stadler WM, Desai AA, Quinn DI, Bukowski R, Poiesz B, Kardinal CG, Lewis N, Makalinao A, Murray P, Torti FM (2008) A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol 61:689-694
14. Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G (2008) Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res 14:3889-3895
15. Henry SP, Zuckerman JE, Rojko J, Hall WC, Harman RJ, Kitchen D, Crooke ST (1997) Toxicological properties of several novel oligonucleotide analogs in mice. Anticancer Drug Des 12:1-14 (Pubitemid 27073340)
16. Krieg AM (2000) Immune effects and mechanisms of action of CpG motifs. Vaccine 19:618-622
17. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760
18. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF, Crooke ST (1997) Immune stimulation - a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 12:421-432 (Pubitemid 27292377)
19. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM (2000) Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164:1617-1624
20. Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ (1997) Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev 7:503-510 (Pubitemid 27491373)
21. McIntyre KW, Lombard-Gillooly K, Perez JR, Kunsch C, Sarmiento UM, Larigan JD, Landreth KT, Narayanan R (1993) A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. Antisense Res Dev 3:309-322 (Pubitemid 24062049)
22. Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G (1993) Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol 45:20372043
23. Zon G (1995) Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity. Toxicol Lett 82-83:419-424
24. Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ (1997) Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 281:810-816 (Pubitemid 27203815)
25. Monteith DK, Geary RS, Leeds JM, Johnston J, Monia BP, Levin AA (1998) Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol Sci 46:365-375 (Pubitemid 29069621)
26. Henry SP, Bolte H, Auletta C, Kornbrust DJ (1997) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120:145-155 (Pubitemid 27223345)
27. Henry SP, Monteith D, Bennett F, Levin AA (1997) Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des 12:409-420 (Pubitemid 27292376)
28. Butler M, Stecker K, Bennett CF (1997) Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 77:379-388 (Pubitemid 27465599)
29. Monteith DK, Horner MJ, Gillett NA, Butler M, Geary R, Burckin T, Ushiro-Watanabe T, Levin AA (1999) Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol Pathol 27:307-317 (Pubitemid 29245041)
30. Levin AA, Yu RZ, Geary RS (2008) Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Crooke ST (ed) Antisense drug technology: principles, strategies and applications, 2nd edn. Taylor and Francis Group, Florida, pp 183-215
31. Wei X, Dai G, Liu Z, Cheng H, Xie Z, Marcucci G, Chan KK (2006) Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry. AAPS J 8:E743-E755
32. Agrawal S, Iyer RP (1997) Perspectives in antisense therapeutics. Pharmacol Ther 76:151-160 (Pubitemid 28078568)
33. Yu RZ, Geary RS, Leeds JM, Watanabe T, Moore M, Fitchett J, Matson J, Burckin T, Templin MV, Levin AA (2001) Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 90:182-193
34. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S (1995) Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49:929-939